NIH Launches Clinical Trial of Epstein-Barr Virus Vaccine
The phase 1 trial is expected to last four years and enroll 40 participants
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
The phase 1 trial is expected to last four years and enroll 40 participants
Only registered members have full access to PracticeUpdate content.